FDA Grants Orphan Drug Designation for inzomelid for the Cryopyrin-Associated Periodic Syndromes (CAPS)

Inzomelid is a potent, selective, orally-available, brain-penetrant NLRP3 inflammasome inhibitor intended for treatment of debilitating inflammatory diseases. It is currently being investigated in phase II trials.

Biospace Inc.